Disclaimer: The Views/Opinions expressed and/or opinions provided in Videos and other content on MedEnrich Website are those of respective speakers. They do not purport to reflect the opinion or views of Dr.Reddy’s Laboratories Limited or its affiliates (collectively Dr.Reddy’s)in any manner whatsoever and accordingly ,Dr.Reddys does not recommend , endorse or make any representation about the veracity and appropriateness of the views ,opinions/ information on MedEnrich website. Content on MedEnrich website may discuss uses and dosage for therapeutic product that may not have been approved in by the relevant regulatory agencies in your country. Dr.Reddy’s does not support , endorse or encourage any off-label use. Please refer to approved label before prescribing.
Duration of trastuzumab in patients with Her2 positive Metastatic Breast Cancer in prolonged remission
Breast Cancer Published 2 years ago
Content
Breast Cancer
1m 21s
Recent advances in triple-negative breast cancer (TNBC)
Published 11 Jul 2022
Metastatic Triple Negative Breast Cancer is still an unmet medical need. TNBC is not just ER-negative , PR-negative & Her2-Negative disease but there are 2 additional biomarkers , PDL1 status for Immunotherapy & germline BRCA status for consideration of PARP inhibitors. A new targeted treatment Sacituzumab Govitecan as recently approved treatment of Metastatic Triple Negative Breast Cancer.
